Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

C4 Therapeutics Inc (CCCC)

C4 Therapeutics Inc (CCCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 350,305
  • Shares Outstanding, K 97,578
  • Annual Sales, $ 35,950 K
  • Annual Income, $ -104,990 K
  • EBIT $ -104 M
  • EBITDA $ -105 M
  • 60-Month Beta 2.85
  • Price/Sales 8.25
  • Price/Cash Flow N/A
  • Price/Book 1.15

Options Overview Details

View History
  • Implied Volatility 112.31% (-21.97%)
  • Historical Volatility 110.58%
  • IV Percentile 12%
  • IV Rank 7.39%
  • IV High 688.26% on 04/07/25
  • IV Low 66.34% on 05/21/25
  • Expected Move (DTE 10) 0.43 (13.85%)
  • Put/Call Vol Ratio 0.52
  • Today's Volume 312
  • Volume Avg (30-Day) 386
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 7,970
  • Open Int (30-Day) 6,892
  • Expected Range 2.70 to 3.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.21
  • Number of Estimates 2
  • High Estimate -0.17
  • Low Estimate -0.25
  • Prior Year -0.37
  • Growth Rate Est. (year over year) +43.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.74 +81.27%
on 02/11/26
3.82 -17.67%
on 03/09/26
+1.30 (+70.92%)
since 02/10/26
3-Month
1.69 +86.08%
on 02/05/26
3.82 -17.67%
on 03/09/26
+0.57 (+21.90%)
since 12/10/25
52-Week
1.09 +188.53%
on 04/17/25
3.82 -17.67%
on 03/09/26
+0.98 (+45.60%)
since 03/10/25

Most Recent Stories

More News
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,...

CCCC : 3.12 (-13.09%)
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later Phase...

CCCC : 3.12 (-13.09%)
C4 Therapeutics to Participate in Upcoming March Conferences

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science,...

CCCC : 3.12 (-13.09%)
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027  Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 WATERTOWN, Mass., Feb....

CCCC : 3.12 (-13.09%)
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,...

CCCC : 3.12 (-13.09%)
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science,...

CCCC : 3.12 (-13.09%)
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,...

CCCC : 3.12 (-13.09%)
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

 Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026...

CCCC : 3.12 (-13.09%)
Novel Immunotherapy Breakthroughs Advance Blood Cancer Treatment

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists have engineered breakthrough cell therapies that can be mass-produced and stored ready-to-use, addressing...

ZLAB : 19.50 (+1.99%)
GTBP : 0.4177 (+0.17%)
ROIV : 29.73 (+0.68%)
CCCC : 3.12 (-13.09%)
BMY : 60.15 (-0.79%)
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,...

CCCC : 3.12 (-13.09%)

Business Summary

C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. C4 Therapeutics...

See More

Key Turning Points

3rd Resistance Point 4.81
2nd Resistance Point 4.31
1st Resistance Point 3.95
Last Price 3.12
1st Support Level 3.10
2nd Support Level 2.60
3rd Support Level 2.24

See More

52-Week High 3.82
Last Price 3.12
Fibonacci 61.8% 2.78
Fibonacci 50% 2.45
Fibonacci 38.2% 2.13
52-Week Low 1.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar